Loading clinical trials...

COMPLETED

The Effectiveness of Varicella Vaccination in Children in Germany

NCT00679796•GlaxoSmithKline

Summary

This study is undertaken to evaluate the effectiveness of currently licensed varicella vaccines under conditions of routine use in a setting where varicella vaccine is included in the childhood immunization calendar.

Detailed Description

Observational, multicenter, population-based, matched case-control study conducted in selected pediatric practices in the Munich area.

Eligibility

Age

1 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male or female child at least one year of age, born on or after July 1 2003.
•Residence in Germany
•At least one previous well-child visit to the practice
•Written informed consent obtained from parents/guardians of the subject as per local requirements.
•Specific inclusion criterion for cases:
•Suspected primary varicella disease (i.e. chickenpox) at the time of study entry

Exclusion Criteria

•Ineligible for varicella vaccination, due to any medical contraindication. These contraindications are:
•* History of hypersensitivity to any of the components of the vaccines
•* Congenital or acquired immunodeficiency
•* Treatment with immunosuppressive therapy
•* HIV-infected patients, when CD4 \< 25% of total lymphocytes
•* Previous history of chickenpox by physician record or parental report.
•* Lack of documented vaccination history (written or computerised practice records or child's vaccination card/booklet).

Locations (33)

GSK Investigational Site

Baldham, Bavaria, Germany

GSK Investigational Site

Deisenhofen, Bavaria, Germany

GSK Investigational Site

Freising, Bavaria, Germany

GSK Investigational Site

Fürstenfeldbruck, Bavaria, Germany

GSK Investigational Site

Gilching, Bavaria, Germany

GSK Investigational Site

Grafing, Bavaria, Germany

GSK Investigational Site

Grafrath, Bavaria, Germany

GSK Investigational Site

Kirchheim, Bavaria, Germany

GSK Investigational Site

Munich, Bavaria, Germany

GSK Investigational Site

Munich, Bavaria, Germany

Key Dates

Start Date

February 1, 2008

Primary Completion Date

October 1, 2010

Completion Date

October 1, 2010

Last Updated

October 29, 2012

Enrollment

1,012

ACTUAL participants

Conditions

Varicella (Chickenpox)Chickenpox Vaccines

Interventions

Varicella (chickenpox) lesion sampling

PROCEDURE

Second Dose of Varicella Vaccine in Healthy Children

NCT07475000

Varicella (Chickenpox)Varicella Immunisation

View study

NOT_YET_RECRUITINGPHASE4

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

NCT06891872

Varicella (chickenpox)MMR Vaccine+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effectiveness of Varicella Vaccination in Children in Germany

Inclusion Criteria

Exclusion Criteria

Second Dose of Varicella Vaccine in Healthy Children

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox